These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22661571)

  • 1. Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
    Ferraris L; Viganò O; Peri A; Tarkowski M; Milani G; Bonora S; Adorni F; Gervasoni C; Clementi E; Di Perri G; Galli M; Riva A
    J Antimicrob Chemother; 2012 Sep; 67(9):2236-42. PubMed ID: 22661571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
    Panagopoulos P; Paraskevis D; Katsarolis I; Sypsa V; Detsika M; Protopapas K; Antoniadou A; Papadopoulos A; Petrikkos G; Hatzakis A
    Int J STD AIDS; 2014 Oct; 25(12):860-5. PubMed ID: 24516079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
    Park WB; Choe PG; Song KH; Jeon JH; Park SW; Kim HB; Kim NJ; Oh MD; Choe KW
    Clin Infect Dis; 2010 Jul; 51(1):101-6. PubMed ID: 20504240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
    Culley CL; Kiang TK; Gilchrist SE; Ensom MH
    Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.
    Floridia M; Ravizza M; Masuelli G; Giacomet V; Martinelli P; Degli Antoni A; Spinillo A; Fiscon M; Francisci D; Liuzzi G; Pinnetti C; Marconi AM; Tamburrini E;
    J Antimicrob Chemother; 2014 May; 69(5):1377-84. PubMed ID: 24370933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
    Puls RL; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe C; Belloso WH; Molina JM; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S;
    Clin Infect Dis; 2010 Oct; 51(7):855-64. PubMed ID: 20735258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.
    Guaraldi G; Cocchi S; Motta A; Ciaffi S; Codeluppi M; Bonora S; Di Benedetto F; Masetti M; Floridia M; Baroncelli S; Pinetti D; D'Avolio A; Bertolini A; Esposito R
    J Antimicrob Chemother; 2008 Dec; 62(6):1356-64. PubMed ID: 18776190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.
    de Lastours V; Ferrari Rafael De Silva E; Daudon M; Porcher R; Loze B; Sauvageon H; Molina JM
    J Antimicrob Chemother; 2013 Aug; 68(8):1850-6. PubMed ID: 23599359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
    Rodríguez-Nóvoa S; Martín-Carbonero L; Barreiro P; González-Pardo G; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS; 2007 Jan; 21(1):41-6. PubMed ID: 17148966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
    Nishijima T; Tsuchiya K; Tanaka N; Joya A; Hamada Y; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    J Antimicrob Chemother; 2014 Dec; 69(12):3320-8. PubMed ID: 25151207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.